Fulcrum Therapeutics (FULC) EPS (Weighted Average and Diluted) (2020 - 2026)
Fulcrum Therapeutics (FULC) reported EPS (Weighted Average and Diluted) of -$0.25 for Q1 2026, up 10.71% year-over-year from -$0.23 in Q1 2025, and up 19.35% quarter-over-quarter from -$0.31 in Q4 2025.
Fulcrum Therapeutics (FULC) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.25 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.25, up 10.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.15 (down 3733.33% YoY), and the FY2025 annual result was -$1.18, down 637.5% from the prior year.
- EPS (Weighted Average and Diluted) rose to -$0.25 in Q1 2026 per FULC's latest filing, from -$0.31 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.87 in Q2 2024 and troughed at -$0.83 in Q2 2022.
- A 5-year average of -$0.33 and a median of -$0.38 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) soared 328.95% in 2024, then slumped 132.18% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.47 in 2022, then rose by 14.89% to -$0.4 in 2023, then surged by 32.5% to -$0.27 in 2024, then declined by 14.81% to -$0.31 in 2025, then rose by 19.35% to -$0.25 in 2026.
- Business Quant data shows FULC's EPS (Weighted Average and Diluted) at -$0.25 in Q1 2026, -$0.31 in Q4 2025, and -$0.31 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.25 |
| Dec 31, 2025 | -0.31 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | -0.28 |
| Mar 31, 2025 | -0.28 |
| Dec 31, 2024 | -0.27 |
| Sep 30, 2024 | -0.35 |
| Jun 30, 2024 | 0.87 |
| Mar 31, 2024 | -0.43 |
| Dec 31, 2023 | -0.40 |
| Sep 30, 2023 | -0.39 |
| Jun 30, 2023 | -0.38 |
| Mar 31, 2023 | -0.41 |
| Dec 31, 2022 | -0.47 |
| Sep 30, 2022 | -0.51 |
| Jun 30, 2022 | -0.83 |
| Mar 31, 2022 | -0.64 |
| Dec 31, 2021 | -0.58 |
| Sep 30, 2021 | -0.57 |
| Jun 30, 2021 | -0.60 |